Background: Gastroesophageal reflux disease (GERD) is a common chronic, relapsing condition that carries a risk of significant morbidity and potential mortality from resultant complications. Proton pump inhibitors (PPIs) remained as the main stay in the therapy of GERD but they do not have any role in increasing the tone of lower esophageal sphincter which is the main pathophysiology of GERD. In this regard addition of prokinetic agent like Itopride may be beneficial in improving the symptoms associated with GERD. So the present study has been taken to compare the healing rates of esophagitis and reduction in symptom scores associated with GERD between Pantoprazole monotherapy and Pantoprazole plus Itopride combination.Methods: 100 patients...
Background/aims: S-isomer (S) pantoprazole is more bioavailable and less dependent on cytochrome 2C1...
Objective: Although some patients may prefer using a particular kind of proton pump inhibitor in gas...
PURPOSE: Patients with gastroesophageal reflux disease without esophagitis show varying response...
Background: The objective of this study was to compare the efficacy of pantoprazole and esomeprazole...
The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to he...
The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to he...
Background: Gastroesophageal reflux disease (GERD) presents in various ways in terms of symptoms and...
The objective of this study was to evaluate the effect of pantoprazole and pregabalin on experimenta...
AB Objective: To assess the efficacy of omeprazole in patients presenting with troublesome reflux sy...
Patients with reflux esophagitis (grade II or III, Savary-Miller, intention-to-treat, n = 256, age r...
Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Previous s...
Background - Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed a...
Background: Systematic assessments of the onset of symptom relief in the treatment of gastroesophage...
Background: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg...
INTRODUCTION: Esomeprazole, the first proton pump inhibitor to be developed as an optical isomer, ha...
Background/aims: S-isomer (S) pantoprazole is more bioavailable and less dependent on cytochrome 2C1...
Objective: Although some patients may prefer using a particular kind of proton pump inhibitor in gas...
PURPOSE: Patients with gastroesophageal reflux disease without esophagitis show varying response...
Background: The objective of this study was to compare the efficacy of pantoprazole and esomeprazole...
The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to he...
The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to he...
Background: Gastroesophageal reflux disease (GERD) presents in various ways in terms of symptoms and...
The objective of this study was to evaluate the effect of pantoprazole and pregabalin on experimenta...
AB Objective: To assess the efficacy of omeprazole in patients presenting with troublesome reflux sy...
Patients with reflux esophagitis (grade II or III, Savary-Miller, intention-to-treat, n = 256, age r...
Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Previous s...
Background - Esomeprazole, an S-isomer of omeprazole, is the first proton pump inhibitor developed a...
Background: Systematic assessments of the onset of symptom relief in the treatment of gastroesophage...
Background: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg...
INTRODUCTION: Esomeprazole, the first proton pump inhibitor to be developed as an optical isomer, ha...
Background/aims: S-isomer (S) pantoprazole is more bioavailable and less dependent on cytochrome 2C1...
Objective: Although some patients may prefer using a particular kind of proton pump inhibitor in gas...
PURPOSE: Patients with gastroesophageal reflux disease without esophagitis show varying response...